Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

L-Carnitine and Reduced C-Reactive Protein Levels

Research synthesisModerate evidenceModerate effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across all 4 studies, L-carnitine supplementation showed beneficial effects on reducing C-reactive protein (CRP) levels, with a predominant moderate effect size. All 4 studies reported statistically significant reductions, though effect magnitude varied from small to moderate. Median study duration was 46 days, and doses ranged from 500 mg/day to 3 g/day, with most evidence coming from meta-analyses and RCTs in clinical populations (migraine, sepsis) and adults with impaired glucose tolerance.

  • Effective dose range: 500 mg/day to 3 g/day
  • Studied populations: adults with migraine, critically ill septic patients, adults with impaired glucose tolerance or diabetes

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Doses and durations vary considerably across studies, and one study did not specify dose, limiting precision of dose-response recommendations.

Generated May 13, 2026
Doses used in studies
  • g/day: 3 (median 3, IQR 33) 1 study
  • mg/day: 500 (median 500, IQR 500500) 1 study
Time to effect
Median: 6.5 weeks · IQR 3.8 weeks9.3 weeks · Range 7 days2.8 months — Reported in 2 of 4 studies
4 of 4 papers
Back to top